Genetic Polymorphism of XRCC1 Correlated with Response to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer

To examine the association between genetic polymorphisms of XRCC1 Arg399Gln(G→A) and response to oxaliplatin-based chemotherapy in advanced colorectal cancer. XRCC1 genotypes of totally 99 patients(37 stage III, 62 stage IV)with advanced colorectal cancer treated with oxaliplatin-based chemotherapy were detected by TaqMan-MGB probe allelic discrimination method. And clinical response of 62 patients in stage IVafter 2 to 3 cycles of chemotherapy were evaluated. Also time to progress (TTP) of all patients were evaluated. Of the genotype frequencies in all patients, up to 52.53?% were G/G genotype, 9.09?% were A/A genotype, and 38.38?% were G/A genotype. The response rate (CR+PR) of 62 patients in stage IV was 61.29?% (19/31). Patients with G/G genotype showed enhanced respond to chemotherapy compared to those with G/A+A/A (x (2)?=?5.6, P?=?0.029; OR?=?3.845, 95?%CI?=?1.231?~?12.01, P?=?0.018). Individuals with the G/G genotype had a TTP of 10.0 (8.88-11.12) months, those with the G/A+A/A genotype had an TTP of 5.0(4.26-5.74) months. The log-rank test was marginally significant (x (2)?=?29.20, P?